Journal of Contemporary Medicine (May 2021)
Evaluation of Surgical and Systemic Treatment Results in Patients with Ductal Carcinoma In Situ
Abstract
Objective: The aim of this study was to evaluate the surgical method and systemic treatment results, recurrence, and mortality rates in patients whose histopathological results were ductal carcinoma in situ (DCIS) following breast surgery in our general surgery clinic. Methods: A retrospective review was made of the preoperative and postoperative histopathological results of all patients who underwent breast surgery in our general surgery clinic between January 2016 and January 2021. The demographic data, clinicopathological features, postoperative systemic treatments, local recurrence (LR) rate, and overall survival (OS) rate of patients whose histopathological results were reported as DCIS were obtained from the data system of our hospital and the national death reporting system. Results: The study group consisted of 24 female patients with a histopathology result of DCIS. The average age of the patients was 49.96 ± 10.61 years. In the localization of the lesions in the breast, 11 (45.8%) were observed as unifocal, 7 (29.2%) as multifocal, and 6 (25%) as multicentric. The most common type of operation was lumpectomy (n = 16, 66.7%). Sentinel lymph node biopsy was performed in 8 patients. The mean follow-up period of the patients after surgery was 32.20 ± 18.22 months. Anti-estrogen hormone therapy (HT) was applied to 21 (87.5%) patients and radiotherapy (RT) to 14 (58.3%) after the operation. There was no recurrence in any of the patients and no mortality was observed. Conclusion: With a multidisciplinary approach and good preoperative staging, as applied in our general surgery clinic, it can be recommended that the most appropriate surgical method is applied, and risk factors determined for DCIS patients. RT is recommended for eligible patients after BCS and HT in estrogen receptor+ patients.
Keywords
